Loading
A phase 3 trial of Pilocarpine in Head and neck squamous cell carcinoma, run by Alberta Health services, completed.
Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients is a phase 3 interventional study registered as NCT00168181 by Alberta Health services, with 220 participants recorded, started 2002-04. Interventions recorded: Submandibular gland Transfer, Salagen. Conditions recorded: Cancer, Head and Neck Cancer.
Linked to the drug Pilocarpine because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pilocarpine, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Pilocarpine and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/